在神经内分泌瘤中使用temozolomide/capecitabine的替代方案
Philipp Melhorn1, Peter Mazal2, Ladislaia Wolff1
1Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
Endocrine-related cancer
|January 12, 2024
概括
修改后的capecitabine/temozolomide (TEMCAP) 疗法在神经内分泌瘤 (NEN) 中显示出有希望的疗效和安全性. 这项研究支持其使用以及对这种神经内分泌瘤治疗的进一步调查.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经内分泌瘤 (NEN) 经常被用capecitabine/temozolomide (CAPTEM) 治疗.
- 在NEN中,CAPTEM的最佳剂量表尚未明确定义.
- 现有的治疗方案各不相同,需要研究更有效,更安全的治疗方案.
研究的目的:
- 评估修改CAPTEM疗法 (TEMCAP) 在NEN患者中的疗效和安全性.
- 评估应答率,无进展生存期 (PFS) 和同时剂量计划的毒性.
- 为了比较新的TEMCAP计划与现有的顺序方案.
主要方法:
- 一个单一中心对40名用TEMCAP治疗的NEN患者进行了回顾性分析.
- 在28天的周期中,TEMCAP涉及同时服用temozolomide (1-5天) 和capecitabine (1-14天).
- 收集的数据包括应答率,PFS,整体存活率和毒性概况.
主要成果:
- 在异质的NEN群体中,PFS的中位数为13.3个月,总生存时间的中位数为31.9个月.
- 在38.9%的患者中观察到部分反应,疾病控制率为75.0%.
- TEMCAP疗法显示出良好的安全性,没有观察到3级或4级毒性.
结论:
- 修改后的TEMCAP计划在患有NEN的患者中有效且耐受良好.
- 这种方案显示出作为神经内分泌瘤的有价值的治疗选择的潜力.
- 需要进一步的前性研究来证实这些发现并优化TEMCAP时间表.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
205
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
205
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527